Anixa Biosciences (ANIX) 10-Q 2022 Q3 Quarterly report

Exhibit 32.2

Statement of Chief Financial Officer

Pursuant to Section 1350 of Title 18 of the United States Code

Pursuant to Section 1350 of Title 18 of the United States Code, the undersigned, Michael J. Catelani, the President, Chief Operating Officer and Chief Financial Officer of Anixa Biosciences, Inc., hereby certifies that:

1.	The Company’s Form 10-Q Quarterly Report for the period ended July 31, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:	/s/ Michael J. Catelani
	Michael J. Catelani
	President, Chief Operating Officer and
	Chief Financial Officer
	(Principal Financial and
September 9, 2022	Accounting Officer)